pbi-200
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 20, 2021 (NCT04901806)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
NTRK2 inhibitor
NTRK3 inhibitor
- Nerve growth factor receptor Trk-AINHIBITOR
NTRK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05692570 | Phase 1 | Sep 9, 2022 | Pyramid Biosciences |
| NCT05238337 | Phase 1 | Feb 24, 2022 | Pyramid Biosciences |
| NCT05690932 | Phase 1 | Feb 24, 2022 | Pyramid Biosciences |
| NCT05160389 | Phase 1 | Nov 17, 2021 | Pyramid Biosciences |
| NCT04901806 | Phase 1/Phase 2 (Phase 2) | Jul 20, 2021 | Pyramid Biosciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pyramid Biosciences | For profit | 5 | 5 | 2 | 2021 |
1 organizations
Page 1 / 1